LeonaBio, Inc.

Listed Company

LONACIK 0001620463NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)FY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-105.60M

Total Assets

$92.15M

Equity

$27.79M

Shares Out

9.34M

Op. Cash Flow

$-45.73M

Business

Athira Pharma, Inc. is a clinical‑stage biopharmaceutical company developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its main products include orally available ATH-1105 and ATH-1020 and previously developed fosgonimeton, all designed as ATH positive modulators to enhance the neurotrophic HGF/MET system for indications such as ALS, Alzheimer’s, Parkinson’s and neuropathic pain. The company’s business centers on discovery, preclinical and clinical development, intellectual property management, and partnering/licensing activities. It conducts clinical trials in the United States and internationally and relies on third‑party CDMOs and strategic partners for manufacturing, supply and potential commercialization.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	18	71	94	61	43
Acquired in-process research and development	68	—	—	—	—
General and administrative	17	26	33	33	21
Legal expense	—	4	—	10	—
Total operating expenses	102	101	125	104	64
Loss from operations	−102	−101	−125	−104	−64
Other income, net	1	4	8	3	334,000
Sermonix pre-funded warrant change in fair value	−5	—	—	—	—
Net loss	−106	−97	−118	−96	−55
Unrealized (loss) gain on available-for-sale securities	−5,000	350,000	2	−2	−421,000
Comprehensive loss attributable to common stockholders	−106	−97	−116	−97	−55
Net loss per share attributable to common stockholders, basic	−24.7	−25.19	−3.09	−2.53	−1.49
Net loss per share attributable to common stockholders, diluted	−24.7	−25.19	−3.09	−2.53	−1.49
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	4	4	38	38	37
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	4	4	38	38	37

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	69	48	91	96	111
Short-term investments	19	3	57	104	143
Prepaid expenses and other current assets	1	4	6	6	5
Total current assets	89	55	155	208	261
Restricted cash	631,000	631,000	631,000	420,000	—
Property and equipment, net	1	2	3	4	4
Operating lease right-of-use asset	535,000	808,000	1	1	1
Other long-term assets	55,000	55,000	448,000	55,000	56,000
Total assets	92	59	160	258	332
Accounts payable	5	319,000	129,000	3	567,000
Accrued liabilities	5	12	18	9	8
Sermonix pre-funded warrant	37	—	—	—	—
Current operating lease liability	465,000	414,000	368,000	326,000	288,000
Total current liabilities	48	13	29	21	9
Operating lease liability, less current portion	338,000	803,000	1	2	2
Milestone Liabilities	15	—	—	—	—
Other long-term liabilities	1	—	—	—	—
Total liabilities	64	14	30	23	11
Common stock, $0.0001 par value; 90,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 9,335,913 and 3,904,049 shares issued and outstanding at December 31,2025 and December 31,2024, respectively	1,000	0	4,000	4,000	4,000
Additional paid-in capital	540	451	440	429	417
Accumulated other comprehensive (loss) income	−4,000	1,000	−349,000	−2	−388,000
Accumulated deficit	−512	−406	−309	−192	−96
Total stockholders' equity	28	45	130	235	321
Total liabilities and stockholders' equity	92	59	160	258	332

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−106	−97	−118	−96	−55
Non-cash consideration for acquired in-process research and development	68	—	—	—	—
Stock-based compensation	6	11	11	11	5
Depreciation expense	1	1	969,000	845,000	479,000
Non-cash lease expense	273,000	241,000	214,000	203,000	155,000
Amortization of premiums and accretion of discounts on available-for-sale securities, net	−329,000	−515,000	−1	−422,000	493,000
Loss on disposal of equipment	—	7,000	—	—	—
Prepaid expenses and other current and long-term assets, net	2	3	−113,000	−1	2
Insurance recovery receivable related to legal settlement	—	2	−2	—	—
Accounts payable and accrued liabilities	−21	−6	7	2	5
Accrued legal settlement	—	−10	—	10	—
Operating lease liability	−414,000	−368,000	−326,000	−15,000	241,000
Other long-term liabilities	−59,000	—	—	—	—
Net cash used in operating activities	−46	−97	−101	−72	−43
Purchases of available-for-sale securities	−38	−14	−28	−95	−299
Maturities of available-for-sale securities	22	69	123	154	279
Purchases of property and equipment	—	−33,000	−304,000	−1	−2
Net cash (used in) provided by investing activities	−16	55	95	58	−4
Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan.	37,000	194,000	493,000	654,000	—
Proceeds from PIPE financing	90	—	—	—	—
Issuance costs from PIPE financing	−8	—	—	—	—
Net cash provided by financing activities	82	194,000	493,000	654,000	97
Net increase (decrease) in cash, cash equivalents and restricted cash	21	−42	−5	−14	50

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro